{"id":"NCT00561470","sponsor":"Sanofi","briefTitle":"Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","officialTitle":"A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2011-02","completion":"2012-06","firstPosted":"2007-11-21","resultsPosted":"2012-09-28","lastUpdate":"2012-09-28"},"enrollment":1226,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Neoplasms","Neoplasm Metastasis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","otherNames":[]},{"type":"DRUG","name":"FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","otherNames":[]},{"type":"DRUG","name":"FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","otherNames":[]}],"arms":[{"label":"Placebo/FOLFIRI","type":"PLACEBO_COMPARATOR"},{"label":"Aflibercept/FOLFIRI","type":"EXPERIMENTAL"}],"summary":"The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease.\n\nThe secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)","effectByArm":[{"arm":"Placebo/FOLFIRI","deltaMin":12.06,"sd":null},{"arm":"Aflibercept/FOLFIRI","deltaMin":13.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0032"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":221,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Chile","Czechia","Denmark","Estonia","France","Germany","Greece","Italy","Netherlands","New Zealand","Norway","Poland","Puerto Rico","Romania","Russia","South Africa","South Korea","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["34789774","32168980","28807738","28761750","26706237","24140268","22949147"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":198,"n":605},"commonTop":["Diarrhoea","Nausea","Fatigue","Stomatitis","Neutropenia"]}}